Friday, February 19, 2016 - 4:35pmESTPfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Now IBRANCE also is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy.1“Today's news gives more women with metastatic breast cancer the opportunity to benefit from this first-in-class medicine”
Now this news from Fred Hutch sounds exciting. But then my pea laywoman brain could only grasp a teensy bit of the article. Fred Hutch talks about "Filling in the 'missing biology' of breast cancer". This study demonstrates the important role of proteomics (proteins) in personalized medicine. So much to absorb, so much to feel excited about. Hurry up, scientists and researchers. Keep it up and find all cancer patients a cure soon, or at least a good and easy treatment to help to see us to old ( or older) age.
|Drip ... drip ... D R I P|
in your thoughts & prayers.
• I AM STRONG • I AM HEALTHY • I AM LOVED •